Abiopharma

ARTIVA BIOTHERAPEUTICS, INC. (ARTV) Reports the reporting period Financial Results ARTIVA BIOTHERAPEUTICS, INC. (ARTV) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: Not disclosed
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 86782
  • 101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow
  • sponsored Phase 2a basket trial, with no patients relapsing or requiring new immunomodulatory agents AlloNK treatment regimen demonstrated a consistent pattern of deep B
  • cell depletion and tolerability results supportive of outpatient administration in community rheumatology settings U.S. Food and Drug Administration (FDA) alignment on a single Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients, with ACR50 at six months as the primary endpoint; trial initiation planned for H2 2026 Multiple oral and poster presentations at EULAR 2026, including a late
    • planned for H2 2026